Home/Filings/4/0001441848-10-000021
4//SEC Filing

Llana Ted 4

Accession 0001441848-10-000021

CIK 0001441848other

Filed

Apr 22, 8:00 PM ET

Accepted

Apr 23, 1:42 PM ET

Size

10.9 KB

Accession

0001441848-10-000021

Insider Transaction Report

Form 4
Period: 2010-04-21
Llana Ted
SVP, Commercial and Corp Dev
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2010-04-21$27.00/sh64,000$1,728,0000 total
    Exercise: $6.17Exp: 2016-01-23Common Stock (64,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2010-04-21$27.00/sh26,693$720,7110 total
    Exercise: $9.95Exp: 2016-08-06Common Stock (26,693 underlying)
  • Disposition to Issuer

    Comon Stock

    2010-04-21$27.00/sh39,893$1,077,1110 total
Footnotes (3)
  • [F1]This stock option was canceled and exchanged for a cash payment of $1,333,120.00 in accordance with the Agreement and Plan of Merger, dated March 9, 2010, among the issuer, Amber Acquisition Inc. and Abbott Laboratories in connection with the merger of Amber Acquisition Inc. with and into the issuer. The cash payment made with respect to this stock option equals the product of (x) the number of option shares canceled multiplied by (y) the difference between the merger consideration ($27 per share) and the exercise price for this stock option.
  • [F2]This stock option was canceled and exchanged for a cash payment of $455,115.65 in accordance with the Agreement and Plan of Merger, dated March 9, 2010, among the issuer, Amber Acquisition Inc. and Abbott Laboratories in connection with the merger of Amber Acquisition Inc. with and into the issuer. The cash payment made with respect to this stock option equals the product of (x) the number of option shares canceled multiplied by (y) the difference between the merger consideration ($27 per share) and the exercise price for this stock option.
  • [F3]This stock option was canceled and exchanged for a cash payment of $455,115.65 in accordance with the Agreement and Plan of Merger, dated March 9, 2010, among the issuer, Amber Acquisition Inc. and Abbott Laboratories in connection with the merger of Amber Acquisition Inc. with and into the issuer. The cash payment made with respect to this stock option equals the product of (x) the number of option shares canceled multiplied by (y) the difference between the merger consideration ($27 per share) and the exercise price for this stock option.

Issuer

FACET BIOTECH CORP

CIK 0001441848

Entity typeother

Related Parties

1
  • filerCIK 0001453531

Filing Metadata

Form type
4
Filed
Apr 22, 8:00 PM ET
Accepted
Apr 23, 1:42 PM ET
Size
10.9 KB